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Ependymin was first discovered as a predominant protein in brain extracellular
fluid in fish and was suggested to be involved in functions mostly related to
learning and memory. Orthologous proteins to ependymin called ependymin-
related proteins (EPDRs) have been found to exist in various tissues from sea
urchins to humans, yet their functional role remains to be revealed. In this study,
the structures of EPDR1 from frog, mouse and human were determined and
analyzed. All of the EPDR1s fold into a dimer using a monomeric subunit that is
mostly made up of two stacking antiparallel -sheets with a curvature on one
side, resulting in the formation of a deep hydrophobic pocket. All six of the
cysteine residues in the monomeric subunit participate in the formation of three
intramolecular disulfide bonds. Other interesting features of EPDR1 include
two asparagine residues with glycosylation and a Ca2+-binding site. The EPDR1
fold is very similar to the folds of bacterial VioE and LolA/LolB, which also use
a similar hydrophobic pocket for their respective functions as a hydrophobic
substrate-binding enzyme and a lipoprotein carrier, respectively. A further fatty-
acid binding assay using EPDR1 suggests that it indeed binds to fatty acids,
presumably via this pocket. Additional interactome analysis of EPDR1 showed
that EPDR1 interacts with insulin-like growth factor 2 receptor and flotillin
proteins, which are known to be involved in protein and vesicle translocation.
1. Introduction
Although ependymin (also known as EPN or EPD) was first
discovered in teleost fish (Shashoua, 1976a,b, 1977; Benowitz
& Shashoua, 1977), ependymin-related proteins are found
widely from sea urchins (Sua´rez-Castillo et al., 2004) to
humans (Apostolopoulos et al., 2001; Gregorio-King et al.,
2002; Nimmrich et al., 2001; Sua´rez-Castillo & Garcı´a-Arrara´s,
2007). As the name implies, ependymin was discovered in the
ependymal zone of goldfish brain, and its level was found to
increase upon a new learning event (Shashoua, 1976a,b, 1977;
Benowitz & Shashoua, 1977). Subsequent studies on epen-
dymin showed that it was the most abundant glycoprotein in
the brain extracellular fluid (ECF) and cerebrospinal fluid of
teleost fish, and that it was involved in various roles related to
memory consolidation, neuronal regeneration and brain
calcium homeostasis (Shashoua, 1991; Schmidt, 1995). Addi-
tional studies indicated that fish ependymin has an influence
on cold adaptation (Tang et al., 1999) and aggressiveness
(Sneddon et al., 2011). Although the detailed cellular
mechanisms underlying the functions of fish ependymin still
remain elusive, the existence of several Ca2+-binding sites led
to the belief that it is a secreted extracellular matrix protein
(Schmidt, 1995; Ganss & Hoffmann, 1993, 2009; Hoffmann &
Schwarz, 1996). Studies using a peptide fragment of fish
ependymin suggested that it activates c-Jun N-terminal kinase
and the downstream AP-1 transcription factor in murine nerve
cells (Shashoua et al., 2001; Adams et al., 2003; Kaska, 2003).
Orthologous proteins to fish ependymin also exist in other
vertebrates, including mammals. For instance, proteins named
mammalian ependymin-related protein 1 (known as MERP1)
exist in both mouse and human. Unlike the brain-specific
expression in fish, the orthologues in mouse and human were
expressed in various normal tissues as well as in cancerous cell
lines (Apostolopoulos et al., 2001; Gregorio-King et al., 2002).
In another study, the human form showed an increased tran-
scription level in colorectal tumor cells and hence was named
UCC1 (upregulated in colorectal cancer gene 1; Nimmrich
et al., 2001). Additionally, the results of mouse phenotyping
(International Mouse Phenotyping Consortium; http://
www.mousephenotype.org/data/genes/MGI:2145369) indicated
that both male and female homozygote MERP1-knockout
mice were normal apart from significant decreases in tibia
length (P = 3.2  107), locomoter activity (hypoactivity; P =
3.9  107) and fat mass (P = 7.4  106). Hereafter, epen-
dymin and its orthologues will all be referred to as ependymin-
related proteins (EPDRs) for simplicity.
In contrast to fish EPDR, which is secreted into the ECF,
the cellular fate of human or rodent EPDR1 was assigned as
lysosomal localization. Most luminal lysosomal proteins that
are folded and processed in endoplasmic reticulum (ER) and
the Golgi complex are targeted specifically to the lysosome by
mannose 6-phosphate (M6P) tagging and their recognition
and sorting by M6P receptors (known as MPRs). Human and
rodent EPDR1s were found in multiple proteomic analyses of
lysosomal proteins isolated using MPR-immobilized beads
(Sleat et al., 1996, 2005, 2006; Kollmann et al., 2005; Tribl et al.,
2005), and the isolated EPDR1 was shown to contain the M6P
modification (Kollmann et al., 2005; Sleat et al., 2006; Lu¨bke
et al., 2009). Furthermore, a lipidosis-induced density shift
experiment demonstrated quite conclusively that mouse
EPDR1 resides within the lysosome (Della Valle et al., 2006).
The protein sequences of all EPDRs generally contain
an ER-targeting signal-peptide sequence at the N-terminus
(Mu¨ller-Schmid et al., 1992). The sequences of EPDRs also
contain four to six highly conserved cysteine residues that are
predicted to form disulfide cross-links (Mu¨ller-Schmid et al.,
1992; Apostolopoulos et al., 2001). Fish EPDR was found to be
glycosylated at two asparagine sites (Benowitz & Shashoua,
1977; Shashoua, 1977; Ko¨nigstorfer et al., 1989), and all known
EPDR sequences from other organisms contain at least two
predicted N-glycosylation sites that do not necessarily align
with the glycosylation sites in fish.
Despite the fact that EPDRs are conserved across species
(Sua´rez-Castillo & Garcı´a-Arrara´s, 2007), studies providing
clues to their function are limited to that from fish, and the
detailed mechanism of action of EPDR remains to be
revealed. At this point, a homology search using the EPDR
protein sequence failed to show any significant similarity to
other proteins of known function. Hence, EPDR represents a
particularly interesting protein that requires further structural
investigation in order to predict its function. In this attempt,
frog (Xenopus tropicalis) EPDR1, mouse (Mus musculus)
EPDR1 and human EPDR1, all without the signal-peptide
sequence, were recombinantly expressed in insect cells and
their structures were determined to 2.0, 2.4 and 2.0 A˚ reso-
lution, respectively, and analyzed. During the course of writing
up this paper, Wei and coworkers reported a 3.0 A˚ resolution
human EPDR1 structure (Wei et al., 2019). Hence, we refer to
their results and also compare their results with ours here.
2. Experimental procedures
2.1. Plasmid cloning
DNAs for human EPDR1 (UniProt ID Q9UM22; residues
38–224), mouse EPDR1 (UniProt ID Q99M71; residues 38–
224) and frog EPDR1 (X. tropicalis; NCBI Accession No.
XP_002939463; residues 38–220), which all exclude the native
N-terminal signal-peptide sequences, were gene-synthesized
(Bioneer, Daejeon, Republic of Korea) with the addition of
N-terminal His8 tags and BamHI/NotI restriction-enzyme
sites. The genes were also codon-optimized for expression in
the Spodoptera frugiperda (Sf9) insect-cell line. The synthe-
sized DNAs were subcloned into pAcGP67A vector (BD
Biosciences, Franklin Lakes, New Jersey, USA) for secreted
expression.
2.2. Protein expression
The conventional method of insect-cell expression using the
Sf9 insect-cell line and baculovirus was used to obtain the
three ependymin-related (EPDR1) proteins. The insect-cell
culture was performed in a 27C incubator or a shaker using
Corning Insectagro medium (Thermo Fisher Scientific,
Waltham, Massaschusetts, USA) supplemented with 1Gibco
Antibiotic Antimycotic (Thermo Fisher Scientific). Genera-
tions of baculovirus encoding the three EPDR1s were
performed by co-transfecting each subcloned plasmid and the
baculovirus DNA (BestBac Linearized Baculovirus DNA,
Expression Systems, Davis, California, USA) into Sf9 cells
according to the manufacturer’s instructions. Further virus
amplifications through multistep infections were subsequently
performed until fourth-passage virus stocks were obtained.
Approximately 1 l of Sf9 cells (2  106 cells ml1) were
infected using the final virus stocks, and the cells were
harvested after two days when the maximum amounts of
proteins were found to be secreted into the supernatant.
Detailed methods for the expression of frog EPDR1 have
been reported elsewhere (Park et al., 2018).
2.3. Protein purification
The three EPDR1s were purified using nickel-affinity
chromatography via the N-terminal His8 tags designed within
the recombinant proteins, followed by size-exclusion chro-
matography (Park et al., 2018). Firstly, stock solutions of 1M
Tris pH 7.5 and 5M NaCl were used to bring the supernatants
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to 50 mM Tris pH 7.5 and 200 mM NaCl, and the pH was
adjusted to pH 7. For about 1 l of harvested supernatant, 20 ml
Ni–NTA (nitrilotriacetic acid) agarose resin (Qiagen, Hilden,
Germany) was used for protein binding. The protein-bound
resin was further washed with 100 ml wash buffer (20 mM
imidazole, 25 mM Tris pH 7.5, 500 mM NaCl) and the protein
was eluted using elution buffer (200 mM imidazole, 25 mM
Tris pH 7.5, 500 mM NaCl). Proteins in the collected fraction
were checked using SDS–PAGE and concentrated using an
Amicon Ultra-15 centrifugal filter (Millipore; Merck, Kenil-
worth, New Jersey, USA) to 10 ml, which was optimal for
loading onto a size-exclusion column (Superdex 200 HR26/60;
GE Healthcare, Little Chalfont, England) that had been pre-
equilibrated with gel-filtration buffer (GFB; 50 mM Tris pH
7.5, 150 mM NaCl). The elution chromatograms of the three
EPDR1s all showed single-peak profiles (Supplementary Fig.
S1). The elution fractions were concentrated to a protein
concentration of 5–10 mg ml1. The absorptivity coefficients
(") of the three EPDR1s at  = 280 nm were calculated from
the numbers of tyrosine and tryptophan residues in the
proteins: human, 1.8 mg1 ml cm1; mouse, 1.8 mg1 ml cm1;
frog, 1.6 mg1 ml cm1. The overall yields of the purified
EPDR1 proteins were marginal: 0.5–1.5 mg per litre of insect-
cell culture. The final proteins were checked again for
homogeneity on SDS–PAGE (Supplementary Fig. S1). Inter-
estingly, the size of human EPDR1 on SDS–PAGE was smaller
than those of mouse and frog EPDR1 (Supplementary Fig.
S1). The three proteins were aliquoted, flash-frozen in liquid
nitrogen and stored in a 80C deep-freeze for crystallization
and further assays.
2.4. Crystallization
The three EPDR1s were screened for crystallization using
commercial screening solutions (Hampton Research, Aliso
Viejo, California, USA) by the hanging-drop method at 22C.
Optimized single crystals of human EPDR1 appeared in well
reservoirs consisting of 15–20%(w/v) PEG 3350, 0.1M citric
acid pH 4.5 or of 15–20% PEG 3350, 0.2MNaCl, 0.1M bis-Tris
pH 5.5. Optimized single crystals of mouse EPDR1 appeared
in a well reservoir consisting of 0.5–1.0M lithium sulfate, 0.5–
1.0M ammonium sulfate, 0.1M sodium citrate pH 5.6. Opti-
mized single crystals of frog EPDR1 appeared in a well
reservoir consisting of 15–20% PEG 8000, 0.2M calcium
acetate, 0.1M sodium cacodylate pH 6.5. All three crystal
forms appeared in 1–3 days in hanging drops at 22C. The
crystals were transferred into cryoprotectant solutions, which
were made by adding glycerol to the reservoir solution to a
final concentration of 20%, and were flash-cooled in liquid
nitrogen for storage and transport to a high-pressure or X-ray
synchrotron facility.
2.5. Xenon pressurization of frog EPDR1 crystals for phase
determination
A single crystal of frog EPDR1 pressurized with xenon gas
was used for phase determination. Xenon pressurization of the
crystals was carried out using a high-pressure cryocooler by
modifying the high-pressure cryocooling method of Kim et al.
(2005). Crystals mounted in cryoloops were placed in the
bottom part of the high-pressure tubing blocked with an end
cap. The upper end of the tubing was then connected to the
xenon-gas cylinder. After the high-pressure tubing had been
firmly connected to the high-pressure cryocooler, 1 MPa xenon
pressure was applied to the crystal and equilibrated for 5 min
at room temperature. While maintaining the pressure, the
liquid-nitrogen bath was quickly lifted up to three-quarters of
the height of the tubing to cryocool the crystal. The crystal was
cooled for about 2 min in the tubing, the remaining xenon
pressure was released and the crystal was transferred into
cryocaps under liquid nitrogen for transport to the synchro-
tron.
2.6. X-ray data collection and structure determination
X-ray diffraction data were collected at 100 K using CCD
detectors (ADSCQuantum 270 and 315) on beamlines 7A and
5C at Pohang Light Source (PLS), Pohang, Republic of Korea
(Table 1). All data were processed and scaled usingHKL-2000
(Otwinowski & Minor, 1997). The phases of the structure
factors for the frog EPDR1 crystal were determined using
single-wavelength anomalous diffraction (SAD) from a single
Xe-derivatized crystal with data collected at  = 1.54 A˚.
Although f 00 at  = 1.54 A˚ is only half the maximum at the Xe
absorption edge, the anomalously scaled data had sufficient
signal for phasing. The anomalously scaled data at 2.9 A˚
resolution were analyzed in PHENIX (Adams et al., 2010),
where five Xe sites were located for experimental phasing.
Automatic experimental phasing followed by density modifi-
cation using PHENIX led to an interpretable electron-density
map showing multiple -sheeted folding of the protein, and
automatic model building within PHENIX generated an initial
model. The PHENIX-generated model was then subjected to
an automated ARP/wARP (Langer et al., 2008) building cycle
via a web service using higher resolution (2.0 A˚) diffraction
data from the frog EPDR1 crystal, in which more complete
model building was performed. Manual model inspection and
corrections of the structure using the electron-density map
were performed in Coot (Emsley & Cowtan, 2004). Only one
molecule of EPDR1 was found in the asymmetric unit of the
frog EPDR1 crystal. The structures of human and mouse
EPDR1 were determined using the frog EPDR1 model via
molecular replacement performed with Phaser (McCoy et al.,
2007). Four molecules of EPDR1 were found in the asym-
metric units of both the mouse and human EPDR1 crystals.
Manual model corrections and building into the structure in
these cases were also performed in Coot. The final refinements
of the three structures were performed using REFMAC5
(Murshudov et al., 2011) with no data cutoff. Structures were
analyzed in Coot and PyMOL (Schro¨dinger, New York, USA)
and structural figures were rendered in PyMOL. The topology
diagram was generated using the Pro-origami web server
(Stivala et al., 2011) and was modified for our figure. Simulated-
annealing OMIT maps were created in PHENIX.
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2.7. Enzyme assay
Lipase and phospholipase assays using the purified human
EPDR1 were performed according to the manufacturers’
protocols. EPDR1 did not show any activities using the Lipase
Activity Assay Kit (catalog No. MAK046; Sigma–Aldrich, St
Louis, Missouri, USA), the Phospholipase D Activity Assay
Kit (catalog No. MAK137; Sigma–Aldrich) or the EnzChek
Direct Phospholipase C Assay Kit (catalog No. E10215;
Thermo Fisher Scientific, Waltham, Massachusetts, USA).
2.8. Fatty-acid-binding assay
A fluorescent probe (1-anilinonaphthalene-8-sulfonic acid;
1,8-ANS) displacement assay of human EPDR1 was
performed using three saturated fatty acids [caproic acid (C6),
lauric acid (C12) and stearic acid (C18)]. All chemicals were
purchased from Sigma–Aldrich (St Louis, Missouri, USA).
The 1,8-ANS binding and displacement assays were based on
methods described in previous studies of fatty-acid-binding
proteins (Kane & Bernlohr, 1996; Shimamoto et al., 2014). The
binding of 1,8-ANS to human EPDR1 was first measured by
the increase in fluorescence (excitation at 355 nm, emission at
460 nm) on the addition of 1,8-ANS to a fixed 1 mM concen-
tration of human EPDR1 in GFB. Subsequent displacements
of 1,8-ANS inferred by the decrease in fluorescence were
measured by adding the three fatty acids to mixtures of 1 mM
human EPDR1 and 50 mM 1,8-ANS in GFB. Increasing
concentrations of caproic acid or lauric acid were added to
mixtures of human EPDR1 and 1,8-ANS, all in a final
concentration of 0.5% ethanol in GFB. For stearic acid, with a
lower water solubility, the experiment was performed in a final
concentration of 2% ethanol in GFB. The experiments were
performed in 96-well plates with 100 ml final volume and were
kept at 25C in the dark for 3 min before measuring the
fluorescence on a multiple plate reader (Wallac Victor 3,
Perkin Elmer, Waltham, Massachusetts, USA). The dissocia-
tion constant (Kd) and IC50 (concentration at 50% inhibition)
values were calculated using a web-based IC50 toolkit (http://
ic50.tk).
2.9. Identification of the EPDR1 interactome
To analyse the interactome of EPDR1, transient expression
of EPDR1 was induced using a pcDNA5/FRT vector (Thermo
Fisher Scientific, Waltham, Massachusetts, USA) encoding
full-length human EPDR1 (1–224) including the N-terminal
signal peptide. The human EPDR1 gene was cloned into the
vector using NheI and BamHI sites. The PCR reaction was
carried out using a purchased human EPDR1 gene (MGC
Human EPDR1, Clone ID 3461888; Dharmacon, Lafayette,
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Table 1
Data-collection and refinement statistics for EPDR1.
Values in parentheses are for the highest resolution shell.
EPDR1 Frog (Xe phasing) Frog (native) Mouse (native) Human (native)
Data collection
Date 25/7/2018 14/6/2018 14/6/2018 22/12/2017
Diffraction source 7A, PLS 5C, PLS 5C, PLS 7A, PLS
Space group P6522 P6522 P21 P43
Detector ADSC Q270 ADSC Q315 ADSC Q315 ADSC Q270
Wavelength (A˚) 1.54001 1.00930 1.00650 0.97935
Oscillation () 1 1 1 1
No. of frames 360 180 360 180
a, b, c (A˚) 61.46, 61.45, 233.84 61.21, 61.21, 236.20 57.00, 59.67, 137.34 55.86, 55.86, 273.77
, ,  () 90, 90, 120 90, 90, 120 90, 101.29, 90 90, 90, 90
Resolution (A˚) 50–2.90 (2.95–2.90) 50–2.00 (2.03–2.00) 50–2.40 (2.44–2.40) 50–2.00 (2.03–2.00)
Rmerge (%) 9.7 (58.2) 8.3 (103.6) 8.3 (42.2) 8.1 (106.3)
Rp.i.m. (%) 2.1 (12.5) 2.0 (23.0) 3.4 (16.5) 3.2 (41.8)
CC1/2 (0.976) (0.911) (0.988) (0.686)
hI/(I)i 71.0 (10.5) 70.5 (4.5) 44.4 (6.9) 37.7 (2.3)
Completeness (%) 99.9 (100.0) 99.7 (100.0) 99.9 (100.0) 99.8 (100.0)
Multiplicity 21.9 (22.5) 19.8 (20.9) 7.2 (7.5) 7.5 (7.4)
Unique reflections 6390 18642 35643 56296
Overall B factor from Wilson plot (A˚2) 63.6 41.0 41.1 45.2
Initial phasing FOM (PHENIX) 0.36 — — —
Refinement
Resolution (A˚) — 2.0 2.4 2.0
NCS molecules in asymmetric unit 1 1 4 4
Rwork/Rfree (%) — 19.4/27.8 18.5/24.0 19.9/23.5
No. of atoms
Protein — 1565 6092 5981
Ligand/ion 4 Xe 1 Ca 6 NAG, 1 FUC
Water — 57 109 166
B factors (A˚2)
Protein (main chain/side chain) — 51.6/59.7 49.7/58.1 51.9/58.2
Water — 54.9 45.0 54.8
R.m.s. deviations
Bond lengths (A˚) — 0.014 0.016 0.018
Bond angles () — 1.74 1.84 1.98
Colorado, USA). A linker (GGGGS) and a FLAG-tag
(DYKDDDDK) were added at the C-terminus of the EPDR1
gene (EPDR1FLAG) by inserting DNA sequences encoding the
linker and the tag into the 30 PCR primer.
U-87MG cells were plated onto a 150 mm dish in DMEM.
30 mg of an empty pcDNA5/FRT vector or the vector
containing the EPDR1FLAG sequence were transfected into
the U-87MG cells using Lipofectamine 2000 (Life Technolo-
gies, Baltimore, Maryland, USA) and Opti-MEM (Life Tech-
nologies) according to the manufacturer’s instructions. After
48 h of incubation, the control medium or the medium
containing the secreted EPDR1FLAG was concentrated using
10 kDa molecular-weight cutoff Amicon Ultra-15 filter units
(Millipore, Cork, Ireland).
1 mg of protein from the medium was incubated with anti-
FLAG M2 agarose beads (Sigma–Aldrich, St Louis, Missouri,
USA) at 4C for 2 h. U-87MG cell lysates were prepared using
cells not subjected to transient expression of EPDR1FLAG.
The U-87MG cells were harvested and lysed in lysis buffer
consisting of 50 mM HEPES pH 7.5, 150 mM NaCl, 70 mM
potassium acetate, 5 mM magnesium acetate, 1% n-dodecyl
-d-maltoside (Thermo Fisher Scientific, Rockford, Illinois,
USA) and protease-inhibitor cocktail (Roche, Mannheim,
Germany) at 4C for 30 min. The cell lysates were centrifuged
at 16 000g for 20 min. 5 mg protein from the supernatant was
incubated at 4C for 1 h with M2 agarose beads pre-bound
with the medium prepared from the U-87MG cell culture
transiently expressing EPDR1FLAG. The beads were washed
five times with the lysis buffer and then twice with 100 mM
Tris–HCl pH 8.5. The FLAG immunoprecipitates were
prepared for mass spectrometry as described previously (In et
al., 2019). Briefly, the bound proteins were eluted from the
beads using 10M urea, reduced with tris(2-carboxyethyl)-
phosphine and alkylated with 2-chloroacetamide. The proteins
were digested by Lys-C endoprotease (Wako, Osaka, Japan)
at 37C for 6 h before being further digested by trypsin
(Promega, Madison, Wisconsin) at 37C for 13 h. The digested
peptides were desalted on reverse-phased C18 Stage Tips
(Rappsilber et al., 2007). The resulting eluates were dried in a
vacuum concentrator and resuspended in 0.1% formic acid.
Liquid chromatography–mass spectrometry analyses were
performed with an EASY-nLC 1000 coupled to a Q-Exactive
Orbitrap mass spectrometer (Thermo Scientific, San Jose,
California, USA) equipped with a custom electrospray ioni-
zation source. Digested peptides were separated on a 150 mm
reversed-phase analytical column (75 mm internal diameter)
packed with C18 AQ resin (3 mm, 10 nm; Bonna-Agela
Technologies, Wilmington, Delaware, USA). The separation
took 120 min using a nonlinear gradient of 4.5–85.5% aceto-
nitrile at a flow rate of 350 nl min1. The mass spectrometer
was automatically switched between full-scan MS and tandem
MS acquisition in a data-dependent mode. Full-scan survey
mass spectra were collected (m/z 300–1800) in an Orbitrap
utilizing an automated gain-control target of three million ions
with a resolution of 70 000. Tandem mass spectra were
acquired using an automated gain-control target of a half a
million ions with a resolution of 17 500. The top 12 most
intense ions were isolated for fragmentation by higher-energy
collisional dissociation. All single-charged and charge-
unassigned precursor ions were discarded.
MS peaks were generated from raw MS files using
MaxQuant (v.1.6.0.1). The Andromeda peptide-search engine
in MaxQuant was used to match the MS peaks against a
concatenated UniProt human database (October 2017
release) and a decoy database constructed with modified
reversing of protein sequences as described previously (Cox &
Mann, 2008). The search parameters were trypsin digestion,
fixed carboxyamidomethyl modifications of cysteine, a
maximum of two missed cleavages, variable oxidation of
methionine, variable acetylation of protein N-termini, variable
deamidation of asparagine and glutamine, and variable
carbamylation of peptide N-termini. The mass tolerances were
4.5 p.p.m. and 20 p.p.m. for precursor and fragment ions,
respectively. Protein inference and quantitation were
performed using MaxQuant with a 1% false discovery rate
(FDR) threshold for both peptides and proteins. Abundances
of the identified proteins were inferred from the MaxLFQ
intensity (Cox et al., 2014). Statistics and visualization were
performed using Perseus (v.1.6.0.2; Tyanova et al., 2016). The
statistical significance of protein abundance difference was
determined using Student’s t-test (FDR < 0.05, S0 = 1).
3. Results and discussion
3.1. Overall structure
Three homologous EPDR1s from human, mouse and frog
were expressed in insect cells, purified and crystallized
(Supplementary Fig. S1). The structures of the three EPDR1s
were determined to resolutions of 2.0, 2.4 and 2.0 A˚, respec-
tively (Table 1). The frog EPDR1 structure was determined
first by direct phasing using single-wavelength anomalous
diffraction (SAD) from a xenon-derivatized crystal, and the
structure was subsequently used as a search model to deter-
mine the mouse and human EPDR1 structures by molecular
replacement. A total of four monomeric subunits of EPDR1
were located in the asymmetric units of the human and mouse
EPDR1 crystals. The refined structures showed average C
r.m.s.d.s of 0.5 A˚ among the four human EPDR1 molecules
and 1.0 A˚ among the four mouse EPDR1 molecules. Only one
molecule of frog EPDR1 was found in the asymmetric unit of
the crystal of frog EPDR1. An alignment of the three EPDR1
sequences based on the determined structures with identity
percentages is shown in Supplementary Fig. S2.
All three structures show identical folds comprised of two
stacked -sheet layers created by 11 -strands arranged in an
antiparallel fashion (6–5–4–3–2–1–11–10–9–8–
7; Fig. 1). The first layer of the -sheet is created by 1–6
(first layer; 6–5–4–3–2–1). The remaining -strands
7–11 along with 1 and 2 form the second layer (2–1–
11–10–9–8–7; Supplementary Fig. S3). The two -sheet
layers extend side-by-side with partially open surfaces, and the
two long and bent 2 and 1 strands in the middle of the fold
create the curvature between the two layers (Fig. 1). The two
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-sheet layers are connected by a 14-residue loop (the 6–7
loop) that crosses over to link 6 and 7 at the opposite sides.
While the first -sheet layer provides a concave surface at the
center of the protein, the second -sheet layer mediates the
dimeric interface (as discussed later). Two tandem -helices
(1 and 2), which are located at the C-terminal end following
11, surround the first -sheet layer. All six cysteine residues
in the EPDR1 sequences participate in forming three disulfide
bonds (Fig. 1 and Supplementary Fig. S2): (i) Cys42 (human
sequence, labeled C1) at the N-terminal end and Cys172
(human sequence, labeled C4) in the 9–10 loop, (ii) Cys88
(human sequence, labeled C2) in the 3–4 loop and Cys222
(human sequence, labeled C6) at the C-terminal end and (iii)
Cys113 (human sequence, labeled C3) in 6 and Cys210
(human sequence, labeled C5) in 2.
Only small differences in the overall structure are observed
among the EPDR1s from human, mouse and frog (Fig. 1). For
instance, the long bent 1 of the mouse and frog EPDR1s,
which is involved in the formation of the first and second
-sheet layers along with 2, is divided into two -strands in
human EPDR1 (labeled 10 and 1 in Fig. 1). Also, the 8–9
and 10–11 loops in frog EPDR1 diverge significantly in
comparison to those from human and mouse. In particular, the
displacement of the 10–11 loop towards 1 in frog EPDR1
confers an altered conformation of the shortened 10 and 11.
Lastly, 2 at the C-terminus of the human and mouse EPDR1s
extends into a loop in frog EPDR1.
3.2. Dimerization of EPDR1
In the asymmetric unit of the human EPDR1 crystal, four
monomeric subunits of EPDR1 were found, which were
associated with other subunits by two perpendicular twofold
axes [Supplementary Fig. S4(a)]. Buried surface areas (BSAs)
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Figure 1
The overall structures of human, mouse and frog EPDR1. A ribbon diagram of human EPDR1 is shown (in yellow) with secondary-structure elements
indicated. The locations of cysteines (C1–C6) and the disulfide bonds are also shown. A ribbon diagram of mouse EPDR1 is shown (in green) with two
asparagine residues and their NAG glycosylation shown as stick models. Although other types of glycosylation were observed at Asn182, only NAG is
shown for clarity (see Fig. 3 for more on glycosylation). A ribbon diagram of frog EPDR1 is shown (in blue) with Ca2+ ions (shown as spheres), four Ca2+-
binding waters (shown as spheres) and direct Ca2+-interacting residues (shown in stick representation). The details of the interaction network stabilizing
the bound Ca2+ ions in frog EPDR1 are shown in Fig. 3(c). Note that the same colors will be used throughout the figures. The superposed structures of
the three EPDR1s are also shown. The superimposed EPDR1 structures show C r.m.s.d.s of 0.8 A˚ (human versus mouse), 1.1 A˚ (human versus frog)
and 1.1 A˚ (mouse versus frog).
of 1900 and 200 A˚2 (both per subunit from PISA analysis;
Krissinel & Henrick, 2007) were created between the subunits.
Judging from the sizes of these areas, the smaller interface
burying 200 A˚2 is only a lattice contact, while the dimeric
surface burying 1900 A˚2 is likely to be a crucial interaction
mode with physiological relevance. In this mode of inter-
action, the second of the two -sheet layers (2–1–11–10–
9–8–7) mediates the dimeric interface (Fig. 2). This same
dimeric interface was conserved in the interaction between the
two dimers found in the asymmetric unit of the mouse EPDR1
crystal [Supplementary Fig. S4(b)]. BSAs of 2300 A˚2 (per
subunit) were calculated for these dimeric interfaces. All other
contacts bury a BSA of less than 500 A˚2, with no conservation
in other crystal forms. In the frog EPDR1 crystal with only one
monomeric subunit in the asymmetric unit, the same dimeric
interface was formed between the crystallographic symmetry
mates [BSA of 2300 A˚2 per subunit; Supplementary Fig.
S4(c)]. The interfacial conservation in all three crystal forms of
EPDR1 supports the association of EPDR1 subunits into a
dimer using the second -sheet layer.
3.3. Glycosylation and Ca2+-binding site
Fish EPDR showed glycosylation at two asparagine sites
(Benowitz & Shashoua, 1977; Shashoua, 1977; Ko¨nigstorfer et
al., 1989), and the human, mouse and frog EPDR1s had two
predicted N-glycosylation sites that were all conserved
(Supplementary Fig. S2). Although glycosylation at these Asn
residues in human and frog EPDR1 was only slightly percei-
vable and was too disordered to be modeled accurately as
sugars, the glycosylation at the two Asn sites (Asn130 and
Asn182) was well ordered in the case of mouse EPDR1
[Figs. 3(a) and 3(b)]. While the sugar modification at Asn130
could be modeled with only one N-acetylglucosamine (NAG),
that at Asn182 was sufficiently ordered to be modeled with
two NAGs (-1,4 glycosidic bond) and one fucose attached to
NAG (-1,4 glycosidic bond). Such sugar modification is as
expected for the initial glycosylation pattern in proteins
expressed in insect cells.
Also, strong electron density for a metal was observed near
Asp121 only in frog EPDR1 [Fig. 3(c)]. Although we do not
have direct evidence, we have modeled this metal as a Ca2+
ion, which is likely to originate from the 0.2M calcium acetate
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Figure 2
The overall dimeric structure of human EPDR1. Ribbon diagrams of
human EPDR1 as dimers are shown as three different views. Secondary-
structure elements are labeled and the locations of cysteine (C1–C6)-
mediated disulfide bonds are also shown.
Figure 3
Views of the asparagine residues with glycosylations (in mouse EPDR1)
(a, b) and the Ca2+-binding site (in frog EPDR1) (c) with experimental
electron densities. (a) In mouse EPDR1, Asn130 is clearly seen to have a
NAG modification. A stimulated-annealing OMIT map of Fo  Fc
difference density was contoured at 1.1. (b) Also in mouse EPDR1,
Asn182 is clearly seen to have a NAG–FUC–NAG modification. A
stimulated-annealing OMIT map of Fo  Fc difference density was
contoured at 1.1. (c) In frog EPDR1, Ca2+ was found to be octahedrally
coordinated by four water molecules and other nearby atoms of Asp121
and Pro122. The water molecules coordinated to Ca2+ are further
stabilized by tight hydrogen-bonding interactions with the nearby
residues Asp124, Glu175 and Tyr177. A stimulated-annealing OMIT
map of Fo  Fc difference density was contoured at 3.0.
condition that was only present in the crystallization reservoir
used to obtain the frog EPDR1 crystal. A tight water and
amino-acid network was observed surrounding the Ca2+ ion.
The Ca2+ ion is octahedrally coordinated by four water
molecules, the side-chain O atom of Asp121 and the main-
chain O atom of Pro122. The four water molecules coordi-
nated to the Ca2+ ion are further stabilized and arranged in
place by hydrogen-bonding interactions with the nearby
residues Asp124, Glu175 and Tyr177 [Fig. 3(c)]. Interestingly,
although Asp121, Pro122, Asp124 and Glu175 are conserved
throughout the frog, mouse and human EPDR1s, a phenyl-
alanine substitutes for Tyr177 of frog EPDR1 in both mouse
and human EPDR1s (Supplementary Fig. S2). Since the
hydroxyl group of Tyr177 stabilizes one of the water molecules
that bind to the Ca2+ ion, it is expected that the mouse and
human EPDR1s would be likely to have weaker binding to the
metal. Future studies on this metal-binding site may provide
insights into the role of the metal in the function of EPDR1.
3.4. Structure-similarity search
The structure of human EPDR1 was subjected to a fold-
similarity search using the DALI server (Holm & Sander,
1995), and the top two highest scoring structures were found
to be the bacterial VioE (r.m.s.d. = 3.7 A˚; Z-score = 14.6) and
the bacterial LolA (r.m.s.d. = 4.0 A˚; Z-score = 12.3). Inter-
estingly, although the sequences of these proteins show low
levels of similarity (sequence identity <10%) to EPDR1
(Supplementary Fig. S5), the topologies of the two -sheet
layered structures formed by 11 antiparallel -strands are
strikingly identical except for some differences in the lengths
of the -strands and some insertions of -helices (Supple-
mentary Figs. S6 and S7).
The highest scoring VioE is one of the multiple enzymes
that mediate the biosynthesis of violacein, which is a purple
pigment, in Chromobacterium violaceum. Although VioE
associates into a dimer in the crystal, the dimeric interaction
mode differed from that of EPDR1 (Supplementary Fig. S6;
Hirano et al., 2008; Ryan et al., 2008). The next most similar,
LolA, is a lipoprotein localization factor that is found in the
periplasm of Gram-negative bacteria. LolA shuttles lipo-
proteins released from the ABC transporter LolCDE to the
outer-membrane anchored LolB. It is interesting to note that
despite having only 8% sequence identity, LolA and LolB
also have identical folds (Takeda et al., 2003). Unlike EPDR1
or VioE, LolA (and LolB) is monomeric in the crystal
(Supplementary Fig. S7). The DALI search results showed no
structurally similar proteins to EPDR1 that are of eukaryotic
origin. Hence, EPDR1 represents a protein in human and
other eukaryotic organisms that uses a fold previously only
known in bacteria.
3.5. Hydrophobic pocket
When the surface of EPDR1 was analyzed, a deep pocket
with a groove volume of 6000 A˚3 (from cleft analysis using
PDBsum; Laskowski et al., 1997) was observed (Fig. 4). This
cavity was located on the concave surface of the first -sheet
layer (6–5–4–3–2–1) and was made up of mostly
hydrophobic residues. A similar hydrophobic cavity made
from the first -sheet layer also exists in VioE (Supplementary
Fig. S6; Hirano et al., 2008; Ryan et al., 2008) and LolA/LolB
(Supplementary Fig. S7; Takeda et al., 2003) and is regarded as
the pocket necessary for their function. For the enzyme VioE
(Hirano et al., 2008; Ryan et al., 2008), this pocket was
proposed to be the active site for binding and catalyzing the
chemical conversion of an as yet unidentified hydrophobic
substrate during the final biosynthesis of violacein. For LolA
and LolB, which function as lipoprotein carriers, the same
pocket was proposed to be the binding site for the acyl chain in
the bacterial lipoprotein.
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Figure 4
Surface colored by atom type (a) and charge-smoothened vacuum contact
electrostatic surface (b) of human EPDR1. (a) The surface rendering (N
atoms in blue, O atoms in red and C atoms in yellow) of dimeric human
EPDR1 shows a deep hydrophobic cleft. The approximate regions of the
hydrophobic pockets are circled in white. (b) The surface of negative and
positive electrostatic potential patches generated using a charge-
smoothened contact potential in PyMOL more clearly illustrates the
hydrophobic pocket located within each of the monomeric subunits in the
EPDR1 dimer. [Note that the negative (red) and positive (blue) charges
scaled in KBT/ec units at pH 7 (KB, Boltzmann constant; ec, charge on the
electron) are only qualitatively useful]. The boundaries of the hydro-
phobic pocket entrances are indicated in black.
In the structure of LolB (Takeda et al., 2003), continuous
electron density was observed in this hydrophobic pocket and
was modeled as polyethylene glycol 2000 monomethyl ether
(PEG MME 2000), which is likely to originate from the
crystallization condition. Also, in a recent structure of human
EPDR1 (Wei et al., 2019) that preceded our study, a ligand was
observed in this cavity and was also modeled as an extended
PEG chain from the crystallization condition. It is interesting
to note that we do not see any electron density for any ligand
in the same region despite the fact that PEGs were used to
crystallize the human and frog EPDR1s. For the enzyme VioE,
a similar region in the pocket contained a PEG molecule that
was also likely to arise from the crystallization condition
(Supplementary Fig. S6; Ryan et al., 2008). Several residues
near the bound PEG in VioE have been assigned as being
critical for its enzyme activity (Hirano et al., 2008; Ryan et al.,
2008), but none were conserved in EPDR1 (Supplementary
Fig. S6).
3.6. Functional prediction
The similarity of the structure of EPDR1 to those of VioE,
LolA and LolB, especially in the hydrophobic pocket created
by using a single -sheet layer, which is important for the
functions of the lipoprotein carrier proteins (LolA/LolB) and
the hydrophobic substrate-binding enzyme (VioE), led us to
propose that the eukaryotic EPDR1 may also bind to an as yet
uncharacterized hydrophobic molecule for its function. From
the clues of a Ca2+-binding site found at the mouth of the
hydrophobic pocket in frog EPDR1 and of EPDR1 localizing
in the lysosome (Della Valle et al., 2006), we tested EPDR1 for
acidic Ca2+-dependent lipase and phospholipase activities.
However, none were detected.
However, when increasing concentrations of a fluorescent
1-anilinonaphthalene-8-sulfonic acid (1,8-ANS) probe were
incubated with human EPDR1, the intensity of 1,8-ANS
fluorescence increased, suggesting that 1,8-ANS bound to
EPDR1 with a Kd of 14 mM (Supplementary Fig. S8).
Because the displacement of 1,8-ANS by fatty acids is often
used to assess the binding of fatty acids (Kane & Bernlohr,
1996; Shimamoto et al., 2014) to fatty-acid-binding proteins, a
similar approach was made using human EPDR1 and the fatty
acids caproic acid (C6), lauric acid (C12) and stearic acid
(C18). The displacement assays suggested that smaller fatty
acids more preferably interact with human EPDR1 (Fig. 5).
Because fatty-acid-binding proteins generally interact with
fatty acids with a higher binding affinity (Kd < 5 mM) towards
fatty acids with larger sizes (Kane & Bernlohr, 1996; Shima-
moto et al., 2014), EPDR1 does not seem to be a specific
binder of fatty acids but rather a general binder of hydro-
phobic molecules, and is perhaps important in sequestering
digested lipids in lysosomes. In this regard, it remains to be
seen whether EPDR1 functions as a hydrophobic molecule-
sequestering protein. Also, future structural analysis of
EPDR1 in the presence of a lipid may reveal in detail whether
the Ca2+ ion is directly involved in binding to a lipid.
It is interesting to note that in the recent study by Wei and
coworkers human EPDR1 was shown to interact with lipo-
somes containing anionic negatively charged lipids such as
bis(monoacylglycero)phosphate (BMP) or ganglioside GM1
at acidic pH (Wei et al., 2019). In the same study, human
EPDR1 was shown to stimulate the activity of neuraminidase-3
while inhibiting neuraminidase-4. From these results, the
authors suggested that EPDR1 may function as a lipid trans-
porter or a lysosomal activator protein.
3.7. Interactome of EPDR1
Since the structure of EPDR1 resembles the fold of
bacterial lipoprotein carrier proteins (LolA/LolB), with the
hydrophobic binding pocket designed for binding lipid-
anchored proteins, an interactome analysis of EPDR1 was
performed to determine whether any known lipid-modified
proteins bind to EPDR1. For this analysis, FLAG-tagged
EPDR1 transiently expressed in U-87MG cells was used.
U-87MG cells were selected for exogenous EPDR1 expression
because the expression levels of both endogenous (http://
www.proteinatlas.org; Uhlen et al., 2010) and exogenous
(Supplementary Fig. S9) EPDR1 in these cells seemed suitable
for mass spectrometry. As the majority of exogenously
expressed EPDR1 (EPDR1FLAG) was found to be secreted
into cell-culture medium after expression (Supplementary Fig.
S9), EPDR1FLAG in the culture medium was pre-bound to
anti-FLAG antibody-conjugated beads. As the initial aim was
to identify the EPDR1 interactors in the cell, whole cell lysates
prepared from U-87MG cells that were not subjected to
transient EPDR1FLAG expression were used to pull down the
EPDR1 interactors because minimizing the total EPDR1
protein in the lysate that may compete with bead-bound
EPDR1FLAG will enhance our chance of capturing EPDR1
interactors in extracto. Immunoprecipitation–mass spectro-
metry (IP-MS) analysis and statistical filtering identified six
proteins as candidate EPDR1 interactors (Fig. 6). All of these
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Figure 5
Fatty-acid binding measured by the displacement of a fluorescent probe
(1,8-ANS) bound to human EPDR1. Fatty-acid binding to human
EPDR1 was inferred by measuring the three fatty-acid (C6, caproic acid;
C12, lauric acid; C18, stearic acid) concentrations necessary to replace
50% of 1,8-ANS (IC50). Note that the C6 and C12 displacement studies
were performed in 0.5% ethanol buffer and that the C18 displacement
study was performed in 2% ethanol buffer owing to the limited solubility
of C18 in water.
proteins displayed an at least tenfold greater abundance in
EPDR1FLAG IP-MS than in control IP-MS, with p values of
less than 0.05.
Among the candidate EPDR1 interactors, IGF2R was the
most prominent EPDR1 binder based on the MS/MS values
observed in EPDR1FLAG IP-MS (Supplementary Table S1).
IGF2R (insulin-like growth factor 2 receptor, also called
cation-independent MPR) is a 2491-residue transmembrane
receptor that transports protein cargos earmarked with M6P
into lysosomes (Brown et al., 2009). As human EPDR1 has
been reported to be modified by M6P and to localize into
lysosomes (Sleat et al., 1996, 2005, 2006; Kollmann et al., 2005;
Tribl et al., 2005; Lu¨bke et al., 2009), the identification of
IGF2R confirms that the expressed EPDR1 is M6P-modified
and that IGF2R is the main M6P receptor utilized by M6P-
modified EPDR1 for its proper lysosomal localization. The
identification of IGF2R also indicates that the interactome
analysis is valid.
Other interesting EPDR1 interactors on the list with
specific subcellular locations in endosomal or plasma
membranes were FLOT1 (flotillin-1) and FLOT2 (flotillin-2).
The two proteins share 48% sequence identity and co-
assemble to form multimeric protein complexes on the
membranes of the late endosomes and lysosomes (Stuermer et
al., 2001; Langhorst et al., 2005; Babuke et al., 2009; Riento et
al., 2009). Flotillin proteins are reported to be involved in the
retraction of plasma membrane vesicles and the endocytosis of
certain proteins (Babuke et al., 2009; Aı¨t-Slimane et al., 2009;
Cremona et al., 2011). Moreover, it is known that FLOT1
undergoes palmitoylation (Morrow et al., 2002) and FLOT2
undergoes both palmitoylation and myristoylation (Neumann-
Giesen et al., 2004). Although it remains to be seen whether
EPDR1 interacts with flotillin via the lipid anchors, judging
from their strong interactions with EPDR1 it can be assumed
that flotillin proteins may be a key component in IGF2R-
mediated lysosomal translocation of EPDR1 or may be
related to EPDR1 function.
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